GIP and Parkinson disease: In addition to their conventional application in the T2DM treatment, several in vitro and in vivo studies [9–14] have evaluated the GLP-1 and GIP pleiotropic actions in extrapancreatic tissues, such as neuroprotective and neurotrophic effects in Parkinson’s disease (PD) models.